Pfizer (PFE) said Monday its phase 3 study of Braftovi combination regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with a type of metastatic colorectal cancer.
The company said Braftovi, in combination with cetuximab and mFOLFOX6, also showed a significant improvement in overall survival compared to patients receiving standard chemotherapy, with or without bevacizumab, a key secondary endpoint in the trial.
The drugmaker said it plans to share the results with the US Food and Drug Administration to potentially support full approval of the Braftovi combination regimen in patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.